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SUMMARY 
Vanilmandelic, homogentisic and homovanillic acid excretions were studied in 
parkinsonian patients on and off L-dopa. 
Vanilmandelic acid excretions were quantitated both by gas-chromatographic 
and calorimetric methods. A marked increase in the excretion of this acid was demon- 
strated in the parkinsonian patient as compared to controls. Although vanilmandelic 
excretion rises under the influence of L-dopa, the increase is much smaller than that 
of free homovanillic acid. The latter consistently accounts for some 18-20~/~ of the 
administered I,-dopa dose. While vanilmandelic acid excretions even under the in- 
fluence of L-dopa correlate well with the patients’ weight, no such correlation could 
be obtained with homovanillic acid. 
Homogentisic acid could not be detected in urine specimens of patients either 
on or off L-dopa. No correlation was observed between the clinical status or response 
to L-dopa of the patients and their excretion of acidic urinary catabolites. 
INTRODUCTION 
In conjunction with studies1p2 of dopa metabolites in the cerebrospinal fluid of 
a series of patients with parkinsonism, urinary excretion studies of homovanillic acid 
(HVA), vanilmandelic acid (VMA) and homogentisic acid (HA) were undertaken. 
HVA determinations utilized the method of Sato3; for both VMA and HA in- 
novations and/or modifications of current methodologies were required, especially in 
the samples obtained from patients receiving r.-dopa therapy. 
No difference was observed between the 24-h urinary excretion values of HVA 
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from parkinsonian patients and normal individuals drawn from the same age group 
as the patients. HA could not be demonstrated in the urine of any of the patients 
either before or after initiation of L-dopa therapy. VMA excretion on tl1e other 11and 
was almost doubled in parkinsonian patients as compared to controls. This paper then 
is concerned with HV’,4, VMA and HA excretion in parkinsonian patients, on and off 
L-dopa, as well as the methodologies employed to measure tl1ese parameters. In the 
latter area the comparison of gas-chromatographic and calorimetric data for the 
determination of VMA is, perhaps, of particular interest. 
METHODS 
Urine collection 
Twenty-four-hour urine specimens were obtained from patients and controls in 
bottles which contained 20 ml of 6 N HCl as a preservative. While tl1e collections were 
being made the bottles were kept on ice, and after the specimens were completed, 
aliquots were frozen immediately until use. The controls, or non-Parkinson urine 
specimens, were obtained from individuals over 50 years old, since Parkinson’s disease 
most commonly manifests itself in this age group. The completeness of various 24-h 
collections was monitored by creatinine determinations. 
H VA determination 
Homovanillic acid was determined by the method of Sato3. 
Homogentisic acid determination 
The method of Stoner and Blivaiss4 was the first used in an attempt to locate 
HA in dopa urines. It was found that such compounds as 3,4_dihydroxyphenylacetic 
acid, 3,4-dihydroxyphenylpyruvic acid, norepinephrine, and dopamine produced in- 
terfering absorbance readings. Although small amounts of these compounds are of 
little consequence in quantitating the gram amounts of HA encountered in alcapton- 
uria, their presence in the dopa urines vitiated any attempt to use the method in the 
current study. 
Six dopa urines were run by an enzymatic assay for HA5 and no HA was detected. 
However, when a 4-,~g spike of the acid was added, it was not recovered in 4 of these 
urines. An additional IO ,ug had to be added before detection occurred. Tl1is suggested 
that levels of less than 3 ,~ug HA/ml of urine or several mg/24 11 would pass undetected. 
Consequently, the following method was developed for the partial purification 
of urine and subsequent qualitative detection of homogentisic acid. The pH of the 
urine was adjusted to 4.0 with NaOH and IO ml added to a Dowex 5oWS4 column 
50-100 mesh, 8 cm x I cm which had previously been washed with 15 ml I ,v NaOH, 
15 ml HzO, 15 ml I N HCl, and 45 ml H,O. The ro-ml eluate was collected and added 
to an AGl-X4 anion column (4 cm x I cm). The column was then rinsed with z ml 
50% methanol, z ml 75% methanol, and 2 ml 90% methanol. Ten mlof IOO”/~ methanol 
were added, followed by g ml of methanol-acetic acid (98: 2, v/v). The HA was then 
eluted from the column witl1 20 ml of the methanol-acetic acid mixture. 
The material was evaporated to dryness at room temperature under vacuum 
and I ml of 0.01 N HCl added. The HA was extracted from the acid with two r.5-ml 
portions of ethyl acetate. This ethyl acetate extract was then dried under vacuum at 
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room temperature and the residue dissolved in I ml methanol, which in turn was 
evaporated on a water bath (So’) to one or two drops. Homogentisic acid alone and 
urine samples spiked with IO ,ug of homogentisic acid were also taken through the 
procedure. 
Chromatographs were developed with benzene-chloroform-acetic acid-water 
(I : 3 : 4: 2) on o.25-mm silica gel plates (Aclsorbosil-1, Applied Science) and with ben- 
zene-chloroform-acetic acid-water (I : 6 : 6 : 2) and benzene-methanol-acetic acid 
(45 : 8:4) on pre-coated silica gel F-254 plates (Merck). Visualization was obtained 
with phenol reagent (Folin-Ciocalteau, Fisher Scientific) followed by 10% Na,CO,. 
The sensitivity of the method corresponds to a detection of 0.5 pg/ml. 
VMA calorimetric determination 
The method of Wybenga and Pileggie for VMA determination appeared suitable 
provided certain precautions were observed. Accurate quantitation demands that a 
series of standards be run together with each series of specimens. The VMA standard 
solution, made by dissolving 6 mg VMA (Calbiochem, Los Angeles) in IOO ml 0.01 iV 
HCl, was stable for somewhat less than two weeks, even when stored at 4’. The color 
reagent addition, removal from ice, and subsequent absorbance readings have to be 
timed carefully to insure reproducibility. Finally, the reading of the urines and the 
urine blanks against water was omitted in favor of reading each sample against its 
own blank. 
VMA gas-chromatographic procedure 
Five ml of urine (pH adjusted to 5.5-6.x) mixed with 5 ml of 0.1 M phosphate 
buffer (pH 6.1) were passed through a column packed with AGI-X4 anion resin 
(6 cm x I cm, Bio-Racl Laboratories, California) previously washed with I I\i NaOH, 
H,O, I N acetic acid, and finally with 0.2 M sodium acetate until equilibrium at pH 
6.1 was reached. The effluent was discarded and VMA eluted from the column with 
12 ml of 3.0 N NaCl. The material was then heated in a boiling water bath in order to 
avoid inhibition of VMA oxidation by other urinary constituents. After the eluate 
cooled to room temperature, 8 ml of I M K&O, were added. VMA standards were 
taken through the same procedure, which thus far is essentially the same procedure 
used in the calorimetric determination of VMA. 
The eluates were divided into two ro-ml portions, one of which was treated as 
a blank. To one ro-ml aliquot was added 0.4 ml of 4% NaIO,. To prevent oxidation, 
0.6 ml of 1o0/ Na,S,O, was added to the blanks. The solutions were then heated at 
50~ for 30 min to oxidize VMA to vanillin. At the end of this period, Na&O, is added 
to the standards and urine samples and NaIO, to the blanks. 
The pH was adjusted to 7.5-7.6 and the vanillin twice extracted with reagent 
grade CH,Cl, (8 ml, 8 ml). To the organic layer were added 5 g Na,SO, (anhydrous) and 
the solution mixed and centrifuged. The supernate was dried under N, to I ml and 
0.040 ml of chloroclifluoroacetic anhyclride (K and K Laboratories, Inc., Plainview, 
New York) added to both samples and blanks. The solutions were left at room tem- 
perature for at least 20 h after which time they were completely dried under N,. Two 
ml of distilled ethyl acetate were added and I ~1 thereof injected into a gas chromato- 
graph equipped with an EC detection unit (Hewlett Packard Model 402 with a 03Ni 
cell). Conditions used for the chromatography were: a 4’ U-shaped column, I.D. 4 mm, 
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packed with h/100 Gas Chrom Q coated with r”/o 2X-60; carrier gas, ()j?o Argon, 
5% methane at a flow rate of 60 ml/mm; oven temperature 120n, flash heater I~o’, 
and EC detector 380’. 
A peak which corresponds to the chlorodifluoroacetic derivative of vanillin 
appeared at 7 min. When VMA itself is chromatographed, before and after treatment 
with chlorodifluoroacetic anhydride, no such peak is observed. Nor does underivatized 
vanillin give a peak of the appropriate retention time. The peak height is proportional 
to the amount of material injected and such a standard curve obtained from \%A 
standards taken through the entire procedure is illustrated in Fig, I. Urines spiked 
with VMA and taken througll the procedure show a proportional increase in peak 
10 20 30 40 50 60 70 
~1s VMA 
Fig. I. Standard curve for the GLC determination of vanilmandelic acid. Points on this curve 
correspond to standards taken through the entire analytical procedure described in the text. 
height at 7 min and urines treated as blanks (VMA not oxidized to vanillin) show 
little or no peaking at the 7-min retention time. Since the sensitivity of the gas chro- 
matograph is subject to change, standards have to be run with every set of urines. 
Precision for the gas-chromatographic method is of the order of 30/ if the initial 
sample contains approximately 30 pg of VMA. Accuracy calculated on the recovery 
of IO- and z4-pg quantities of VMA added to the urine samples was of the order of 
@3.1 & 6.6%. 
RESULTS 
HVA 
No difference was observed in baseline excretions (Le., pre-dopa) of HVA as 
compared to normal controls, which were 4.0 & 1.4 mg/z4 h and 3.8 l 1.7 mg/z4 11 
respectively. As reported by others ‘$I3 HVA excretion rose sharply with the dose of 
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ingested L-dopa. Approximately 18-20~/~ of a given dose 
agent was recoverable as free HVA in the urine (Table I). 
TABLE I 
AVERAGE HVA EXCRETION OF L-DOPA PATIENTS 
L-Dopa Number H VA average 
(vamslday) tested (mgl+ h f SD) 
0 15 4.0 + I.4 
2 5 427 i 223 
4 2 645 
2 14 1100 9 6 f 1‘59 
I3 f 338 
7.5 6 1401 i 374 
213 
of the chemotherapeutic 
HA 
As pointed out in the introduction, no HA was recovered from any of the urines 
tested either pre or post dopa. The methodology was adequate to pick up readily as 
little as 0.5 mg HA/l of urine. This finding was in accord with that of CotziaP and in 
contrast to that reported by Arras and Baileya. 
VMA 
Both the calorimetric and the gas-chromatographic procedures show an in- 
creased VMA excretion in the parkinsonian patient as compared to normals (Table II). 
TABLE II 
AVERAGE VMA EXCRETION OF CONTROLS AND PARKINSON PATIENTS 
Subject Method Number VMA average 
tested (mgl24 h * SD) 
Controls* Calorimetric IO 5.4 * 1.6 
Parkinsonian * Calorimetric 32 6.8 * 2.4 
Controls+ Calorimetric 9 5.7 i 2.2 
Parkinsonian+ Calorimetric 6 7.3 f 2.0 
Controls+ Gas chromatography 9 2.9 i 1.6 
Parkinsonian’ Gas chromatography II 5.2 f 2.1 
Subjects fell into two groups. Group I urines* were analyzed calorimetrically only. Group II+ 
represents a different group of controls and patients whose urines were analyzed both colorimetri- 
tally and by GLC. 
The preliminary work was done calorimetrically; with recognition of the fact that 
gas-chromatographic procedures for urinary VMAXO-la in general yield lower values 
than calorimetric ones, the question arose whether the observed increases (6.8 mg/zq h 
for 27 parkinsonian patients as compared to 5.2 mg/z4 h for 5 controlP) were in fact 
due to VMA or to whatever substance contributes to the color of the spectrophoto- 
metric method. The gas-chromatographic procedure which was then developed not 
only confirmed the calorimetric data but sharply accentuated the difference between 
controls and parkinsonian patients. The implication is that the increase noted in the 
latter group by the calorimetric method was de facto due to VMA so that on a per- 
centage basis the error incurred by the calorimetric method is much greater for the 
controls than for the patients. 
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Urinary VMA, as did HVA, rose as the L-dopa dose increased (Table III). How- 
ever the absolute increase is of a far smaller order of magnitude than the HVA in- 
crease nor is the percentage of L-dopa converted to VMA constant. Rather one finds 
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Fig. 2. Twenty-four-hour urinary excretion of vanilmandelic acid us. weight of patients on 5 grams 
daily dose of L-dopa. 
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Another major difference between the pattern of metabolism of HVA and VMA is 
that the amount of a given dose of L-dopa metabolized to VMA correlates strikingly 
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Fig. 3. Twenty-four-hour urinary excretion of homovanillic acid us. weight of patients on 5 grams 
daily dose of L-dopa. 
DISCUSSION 
A defect in the handling of basal ganglia dopamine by the parkinsonian patient 
has been amply documented and is in fact reflected in cerebrospinal fluid HVA level&a. 
However the total amount of dopamine in the involved areas represents such a small 
percentage of the total dopamine metabolism of the body that the alterations remain 
undetectable in urinary excretion studies. Parallel findings were recently reported by 
Gruendig and Gerstenbrandl* who discovered abnormalities in specific amino acid and 
transaminase levels in the cerebrospinal fluid of parkinsonian patients which were not 
demonstrable in blood serum obtained simultaneously from the same patients. 
It is then correspondingly surprising to find VMA excretions increased markedly 
in the parkinsonian patients. On the other hand it is the third tyrosine catabolite 
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showing sufficiently extensive aberrations in metabolism to be documentable by 
urinary analysis. The excretion of methoxytyraminel5 and of $-hydroxyphenylpyruvic 
acidI were previously reported as showing marked changes in the parkinsonian 
patient. 
As a matter of fact it was this increase in j-hydroxyphenylpyruvic acid which 
prompted the HA work reported in the current manuscript, since p-hydroxyphenyl- 
pyruvic is the immediate precursor of HA. From the lack of HA in the parkinsonian 
urine it is evident that conversion of HA to fumarylacetoacetate is not affected by the 
disease. It also supports the hypothesis raised in tile earlier paper that the elevation 
of $-hydroxyphenylpyruvic acid is due to increases in liver tyrosine transaminase 
levels rather than to a block in the metabolism of the keto acid. Regulation of hepatic 
tyrosine transaminase activity ilz 7ho by norepinephrine and pyridoxal phosphate 
has been demonstrated1771*. 
The significance of the elevated VMA levels of the parkinsonian patient is 
difficult to asses. In concert with the above arguments it is probably a symptom of 
systemic involvement in the disease rather than a finding which can be directly 
attributed to the altered central nervous system metabolism of dopamine. Goodall 
and AltonI infused small doses (ca. I mg) of radioactively labelled dopamine into 
three parkinsonian patients and six normal subjects and monitored 14C excretions. 
They were most impressed by a decrease in the percent of the dose excreted as free 
norepinephrine. However a scrutiny of the percentage of the 14C excreted as VMA 
plus its precursor dihydroxymandelic acid supports the concept of an increased nore- 
pinephrine (and/or epinephrine) metabolism. Finally, Tissot15 reported 24-h urinaq 
VMA excretion values for five Parkinson patients (6.o~ lsr 4.03 mg) and zo normal 
subjects (3.56 r+ 1.1 mg) which closely parallel our own data. 
Under the influence of orally administered L-dopa both urinary HVA and VMA 
rose. Free HVA rather consistently accounted for 18-zoo/; of the administered dose 
of L-dopa. 1Vhile \‘MA rose with the administered dose the percent of the dose ex- 
creted in this form fell progressively from 0.74 ($6 for a z-g/day to 0.3So/h for a 7.5-g/day 
dose. Also there is the striking direct correlation between body weight and the amount 
of administered L-dopa excreted as V&IA, a relationship not detectable for HVA. 
These relationships appear to emphasize that the catabolite VRIA cannot be obtained 
except through either of the physiologically active compounds norepinephrine and 
epinephrine. 
As described in the earlier paper2 some correlations exist between the clinical 
status of parkinsonian patients and the measurement of some of the dopa catabolites 
in cerebrospinal fluid. Urines from the Group I patients (see Table II) were drawn 
from the same population as that used for the cerebrospinal fluid studies. In the case 
of the urinary catabolites of L-dopa, free HVA and free VMA, no carrelation was 
obtained between their excretion and the clinical status or response to L-dopa of the 
patients. 
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